The Wistar Institute

SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium. Dr. Conejo-Garcia will be giving the opening keynote address on Friday, September 20, 2024. During the keynote address, Dr. Conejo-Garcia will discuss Anixa's chimeric antigen receptor-T cell (CAR-T) technology, which is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology. "I am pleased to discuss this novel FSHR-mediated CAR-T technology at the Ovarian Cancer Research Symposium and to share ideas and advance the field of ovarian cancer research," stated Dr. Conejo-Garcia. "Anixa and its development partner, Moffitt Cancer Center, have been working together to advance this ovarian cancer therapy and we are excited about the clinical results to date—with the treatment appearing to be safe and well-tolerated, and some patients exhibiting tumor necrosis. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer." More information about the event may be found at: https://rivkin.org/symposia/ocrs/. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact: Mike Catelani President, COO & CFO mcatelani@anixa.com 408-708-9808 View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-therapy-at-the-rivkin-center-aacr-15th-biennial-ovarian-cancer-research-symposium-302233678.html SOURCE Anixa Biosciences, Inc.

MIAMI BEACH, Fla., July 30, 2024 /PRNewswire/ -- Immorta Bio Inc, a scientific longevity company dedicated to "Treating Diseases of Aging and Treating Aging as Disease™" announced today the appointment of Dr. Russel Kaufman to the Company's Board of Directors. Continue Reading Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors Dr. Russel Kaufman is a venture partner at Pappas Capital, as well as President Emeritus of The Wistar Institute, the nation's revered first independent institution devoted to medical research. Prior to Wistar, Dr. Kaufman was associated with Duke University, for over 25 years, with multiple professional and administrative appointments, including Professor of Medicine, Chief, Division of Medical Oncology and Transplantation, Dean of School of Medicine, among others. He is considered a Key Opinion Leader in the areas of Translational Oncology, Stem Cells, and Genomics. "I had the privilege of serving on the board of Dr. Reznik's successful previous company, Biorasi, and I am honored to collaborate with him and his team on this exciting new venture, Immorta Bio," said Dr. Russel Kaufman. "Having witnessed Dr. Reznik's perseverance, talent, and executive expertise in translational medicine and clinical trials, I am confident in the potential of this new endeavor. The company's focus on longevity, combined with its cutting-edge technologies in cellular rejuvenation and senolytic immunotherapy, makes this undertaking particularly exciting. I am very impressed by the rapid progress the company has made, advancing from formation to IND filing with the FDA in just one year. While such accelerated growth is exceptional, it is characteristic of Dr. Reznik's leadership and the remarkable teams he leads." "In our past years of working together, Dr. Kaufman has provided extremely valuable inputs in the areas of science, medicine and business. Having someone on our board who excels in all three disciplines and navigates seamlessly across them is a major privilege," said Dr. Boris Reznik. "As we are advancing our therapeutic platforms into the clinic, we believe Dr. Kaufman's experience, guidance and leadership will strongly position Immorta Bio to rapidly translate our technologies into lifesaving medicines." Dr. Kaufman represents an ideal combination of scientific and business expertise. He has significantly influenced and shaped policy at prestigious institutions such as the National Institutes of Health, the American Cancer Society, and the National Academy of Sciences. His corporate experience includes board roles at the CEO Council for Growth in Philadelphia, BioAdvance, Osage Ventures, Militia Hill Ventures, Biorasi, Neuland Pharmaceutical Labs, and Credit Suisse (SAB). Additionally, Dr. Kaufman has published over 100 scientific reports and his work has garnered more than 2,000 citations. About Immorta Bio Immorta Bio is a longevity-focused biotechnology company developing efficient and practical personalized cellular therapeutic platforms focused on Treating Diseases of Aging and Treating Aging as Disease™. Our therapeutic candidates target unmet need indications across various organ systems. By developing personalized cellular therapies for aging-related diseases, we have the potential to significantly extend our patients' healthy longevity. For more information, please visit the Immorta Bio website at or find them on X at . Company Contact Dr. Boris Reznik Immorta Bio +1 305-632-2939 @immortabio Media Contact David Schull Russo Partners, LLC [email protected] SOURCE Immorta Bio, Inc.

SAN JOSE, Calif., July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024, in Dublin, Ireland. The presentation, titled "Phase I Clinical Trial of Autologous T-cells Genetically Engineered with a Chimeric Receptor to Target the Follicle Stimulating Hormone Receptor (FSHR) in Recurrent Ovarian Cancer (OVCA)," will be presented by the study's principal investigator, Dr. Robert Wenham, Chair of Gynecologic Oncology at Moffitt Cancer Center, Anixa's collaboration partner. About Anixa's CAR-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology) Anixa's chimeric antigen receptor T-cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor T-cell) therapy, a new type of CAR-T. Anixa's FSHR-mediated CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact: Mike Catelani President, COO & CFO [email protected] 408-708-9808 SOURCE Anixa Biosciences, Inc.